• Publications
  • Influence
The dawning era of polymer therapeutics
  • R. Duncan
  • Chemistry, Medicine
  • Nature Reviews Drug Discovery
  • 1 May 2003
As we enter the twenty-first century, research at the interface of polymer chemistry and the biomedical sciences has given rise to the first nano-sized (5–100 nm) polymer-based pharmaceuticals, theExpand
  • 2,651
  • 51
Polymer conjugates as anticancer nanomedicines
  • R. Duncan
  • Chemistry, Medicine
  • Nature Reviews Cancer
  • 1 September 2006
The transfer of polymer–protein conjugates into routine clinical use, and the clinical development of polymer–anticancer-drug conjugates, both as single agents and as components of combinationExpand
  • 1,637
  • 44
  • PDF
Nanomedicine(s) under the microscope.
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable ofExpand
  • 726
  • 22
Dendrimer biocompatibility and toxicity.
The field of biomedical dendrimers is still in its infancy, but the explosion of interest in dendrimers and dendronised polymers as inherently active therapeutic agents, as vectors for targetedExpand
  • 909
  • 18
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
PK1 comprises doxorubicin covalently bound to N -(2-hydroxypropyl)methacrylamide copolymer by a peptidyl linker. Following cellular uptake via pinocytosis, the linker is cleaved by lysosomal enzymes,Expand
  • 642
  • 10
Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues
The objective of this study was to investigate the molecular weight (MW) and time‐dependence of the phenomenon termed “the enhanced permeability and retention”(EPR) effect in solid tumor, inExpand
  • 408
  • 10
Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.
More than 40 nanomedicines are already in routine clinical use with a growing number following in preclinical and clinical development. The therapeutic objectives are often enhanced disease-specificExpand
  • 239
  • 10
Polymer conjugates: nanosized medicines for treating cancer.
Interdisciplinary research at the interface of polymer chemistry and the biomedical sciences has produced the first polymer-based nanomedicines for the diagnosis and treatment of cancer. TheseExpand
  • 386
  • 9
Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics.
Since the early 1990s polymer-protein conjugates (included PEGylated enzymes and cytokines), polymeric drugs and polymeric sequestrants have been entering the market as innovative polymer-basedExpand
  • 202
  • 7
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractoryExpand
  • 229
  • 6
  • PDF